Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency

1 Jan 2024

Abstract excerpt

Meningiomas are the most common primary intracranial tumors,1 and are mostly treated with surgery and ionizing radiation.2 A subgroup of meningiomas recur despite multimodal therapy, and medical treatments are actively being investigated for meningiomas that are resistant to standard interventions.3 Immune checkpoint inhibitors (ICI) that target interactions between programmed death receptor (PD-1) and programmed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Meningioma and schwannoma management
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38957162
DOI: 10.1093/noajnl/vdae092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiencyPMID 38957162Read ↗

Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningiomaSemantic proximity Read ↗

Recent advances in managing/understanding meningiomaSemantic proximity Read ↗

Meningioma epigenetic grouping reveals biologic drivers and therapeutic vulnerabilitiesSemantic proximity Read ↗

Meningioma epigenetic grouping reveals biologic drivers and therapeutic vulnerabilitiesSemantic proximity Read ↗

[MOLECULAR PATHOLOGY OF MENINGIOMAS].Semantic proximity Read ↗

Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastomaSemantic proximity Read ↗

Genomic landscape of intracranial meningiomas.Semantic proximity Read ↗

Molecular characteristics of meningiomasSemantic proximity Read ↗

Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.Semantic proximity Read ↗

Medical management of meningioma in the era of precision medicine.Semantic proximity Read ↗

[The Potential of Personalized/Precision Medicine for Meningiomas].Semantic proximity Read ↗

Current treatment options for meningioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.